Copay help by condition · Immune system, transplant and skin · read 2026-11-08
Psoriatic arthritis (PsA): which charitable copay funds are open
The one fund we hold for Psoriatic arthritis is closed or at capacity right now (read 2026-11-08).
Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Psoriatic arthritis
- Closed or at capacityPsoriatic arthritis (PsA)
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $3,500Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
Drugs whose FDA label names Psoriatic arthritis
14 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 11 have a program (in our assistance finder or on the program's own page) and 3 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Orencia Abatacept Every route for this drug | ... the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). Label on openFDA, read 2026-11-10 | RA Medication Assistance (Multiple Programs) Bristol Myers Squibb Patient Assistance Foundation (program page) | selected by CMS for 2028; price not yet published |
| Otezla Apremilast Every route for this drug | Active psoriatic arthritis ( 1. Label on openFDA, read 2026-11-10 | Otezla Support (via Amgen) Amgen Safety Net Foundation (program page) | $1,650.00 for a 30-day supply, effective 2027-01-01 |
| Enbrel Etanercept Every route for this drug | Psoriatic Arthritis (PsA) ( 1. Label on openFDA, read 2026-11-10 | Enbrel Support (via Amgen) RA Medication Assistance (Multiple Programs) Amgen Safety Net Foundation (program page) | $2,418.70 for a 30-day supply, effective 2027-01-01 |
| Cosentyx Secukinumab Every route for this drug | ... active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. Label on openFDA, read 2026-11-10 | Cosentyx Connect (via Novartis) Limited Novartis Patient Assistance Foundation (NPAF) (program page) | selected by CMS for 2028; price not yet published |
| Xeljanz Tofacitinib Every route for this drug | Active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. Label on openFDA, read 2026-11-10 | Pfizer RxPathways Limited no new patients starting July 1, 2026 RA Medication Assistance (Multiple Programs) | selected by CMS for 2028; price not yet published |
| Stelara Ustekinumab Every route for this drug | Active psoriatic arthritis in adults and pediatric patients 6 years of age and older. Label on openFDA, read 2026-11-10 | Stelara Support (via Janssen/J&J) J&J Patient Assistance Foundation (JJPAF) | $4,822.00 for a 30-day supply, effective 2027-01-01 |
| Humira Adalimumab Every route for this drug | Psoriatic Arthritis (PsA) ( 1. Label on openFDA, read 2026-11-10 | Humira Complete (via myAbbVie Assist) myAbbVie Assist RA Medication Assistance (Multiple Programs) | not in the CMS negotiated-price file |
| Simponi Golimumab Every route for this drug | Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1. Label on openFDA, read 2026-11-10 | Johnson & Johnson Patient Assistance Program | not in the CMS negotiated-price file |
| Tremfya Guselkumab Every route for this drug | ... adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis. Label on openFDA, read 2026-11-10 | J&J Patient Assistance Foundation (JJPAF) | not in the CMS negotiated-price file |
| Taltz Ixekizumab Every route for this drug | ... adults with active psoriatic arthritis. Label on openFDA, read 2026-11-10 | Lilly Cares | not in the CMS negotiated-price file |
| Skyrizi Risankizumab-Rzaa Every route for this drug | ... active psoriatic arthritis in adults and pediatric patients 6 years of age and older. Label on openFDA, read 2026-11-10 | Skyrizi Complete (via AbbVie) myAbbVie Assist | not in the CMS negotiated-price file |
| Cimzia Certolizumab Pegol | Treatment of adult patients with active psoriatic arthritis. Label on openFDA, read 2026-11-10 | not in our assistance finder | selected by CMS for 2028; price not yet published |
| Remicade Infliximab | Psoriatic Arthritis : reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
1 drug whose label names more than 8 conditions
Broad labels, such as corticosteroids, list many conditions in one sentence. They are shown apart so they do not crowd the drugs written for Psoriatic arthritis.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Acthar Corticotropin | Psoriatic arthritis; Label on openFDA, read 2026-11-10 | not in our assistance finder | not in the CMS negotiated-price file |
Related conditions
No broader or more specific condition page for this one.
Group: Immune system, transplant and skin. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-08. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: psoriatic-arthritis.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Psoriatic arthritis?
As read on 2026-11-08, none of the 1 funds we hold for Psoriatic arthritis say they are open. Funds reopen, so use the alert on this page.
Which organizations run funds for Psoriatic arthritis?
TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-08). We do not promise a fund is still in that state today.